NCT07158086 Molecular Underpinnings of Heart Failure, Integrative Multi-Omics, and Non-Coding RNA Profiling
| NCT ID | NCT07158086 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Zurich |
| Condition | Heart Failure |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2025-02-01 |
| Primary Completion | 2030-11-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2025-02-01 with a primary completion date of 2030-11-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The main objective of the study is to achieve a comprehensive phenotyping of patients with heart failure, combining detailed clinical characterization with in-depth molecular profiling. By integrating clinical data with cutting-edge multi-omics techniques (including transcriptomics, epigenomics, and proteomics), this research aims to identify molecular signatures, particularly non-coding RNAs (ncRNAs), that are linked to the onset and progression of HF. Through advanced molecular profiling of biological samples and the analysis of clinical parameters, including advanced imaging, hemodynamic profiling, and biomarker analysis, the study will contribute to the deep phenotyping of HF patients. The secondary objective aims to uncover potential biomarkers that may serve as predictive indicators of disease progression and identify novel therapeutic targets, offering promising avenues for future treatments in this challenging patient population.
Eligibility Criteria
INCLUSION CRITERIA * Female and Male, age ≥18 years at screening. * Diagnosis of Heart Failure according to ESC Heart Failure Guidelines * Ability to understand the requirements of the study and to provide informed consent. * Willingness to undergo follow-up. EXCLUSION CRITERIA Patients will be excluded if they meet any of the following conditions: * Active malignancy or history of cancer with ongoing treatment (e.g., chemotherapy, radiotherapy, immunotherapy). * Autoimmune or systemic inflammatory diseases. * Concomitant infections, including acute systemic infections (e.g., sepsis, pneumonia) or chronic infections with systemic impact (e.g., HIV, hepatitis B/C with elevated transaminases). Other exclusion criteria: * Age\<18 years old * Inability to provide written informed consent
Contact & Investigator
Jan A Kleeberger, MD
PRINCIPAL INVESTIGATOR
Universitätsspital Zürich
Frequently Asked Questions
Who can join the NCT07158086 clinical trial?
This trial is open to participants of all sexes, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07158086 currently recruiting?
Yes, NCT07158086 is actively recruiting participants. Contact the research team at janalphard.kleeberger@usz.ch for enrollment information.
Where is the NCT07158086 trial being conducted?
This trial is being conducted at Zurich, Switzerland.
Who is sponsoring the NCT07158086 clinical trial?
NCT07158086 is sponsored by University of Zurich. The principal investigator is Jan A Kleeberger, MD at Universitätsspital Zürich. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.